Safe Prescribing Practices for Muscle Relaxants and Other Medications

Introduction to Safe Prescribing

The FDA recommends against co-prescribing opioids and benzodiazepines due to increased mortality rates, which are 3-10 times higher in patients co-prescribed these medications compared to opioids alone, according to the FDA and supported by evidence 1
The American Geriatrics Society and other authorities emphasize the importance of safe prescribing practices to minimize risks associated with muscle relaxants and other medications 2, 3

Co-prescription of opioids and benzodiazepines is associated with a high risk of mortality, with rates 3-10 times higher compared to opioids alone, as warned by the FDA 1
Combining muscle relaxants with opioids increases the risk of respiratory depression and CNS effects, and should be avoided when possible, especially in outpatient patients, as recommended by authorities 1
The combination of muscle relaxants and other CNS depressants can cause additive sedation, dizziness, and cognitive impairment, highlighting the need for cautious prescribing practices 4

Benzodiazepines (e.g., diazepam) are associated with a high risk of additive CNS depression, according to the American Geriatrics Society, and should be used with caution 2
Carisoprodol is concerning due to its dependence potential and higher toxicity, as noted by the American Geriatrics Society, and its use should be carefully considered 2
Succinylcholine is contraindicated in patients with myopathies and can cause life-threatening hyperkalemia, emphasizing the need for careful patient selection 3

Cisatracurium is the preferred non-depolarizing agent for most patients, especially those with renal or hepatic impairment, due to its predictable pharmacokinetics, as recommended by the American Society of Anesthesiologists 3
Rocuronium is an alternative to succinylcholine for rapid sequence induction at doses >0.9 mg/kg, offering a safer option in certain clinical scenarios 3
Sugammadex is the preferred agent for reversal of muscle relaxants, with recommended doses of 2 mg/kg for moderate blockade, 4 mg/kg for deep blockade, and 8 mg/kg for immediate reversal, as supported by evidence 3

In elderly patients, cisatracurium is preferred due to its predictable pharmacokinetics, reducing the risk of adverse events in this vulnerable population 3
In patients with renal failure, cisatracurium is recommended, while steroidal agents should be avoided to minimize toxicity 3
In patients with hepatic impairment, cisatracurium is the preferred choice, highlighting its safety profile in patients with liver disease 3
In patients with neuromuscular disease, succinylcholine should be avoided, and reduced doses of non-depolarizing agents should be used to prevent complications 5

Intraoperative monitoring of neuromuscular blockade is strongly recommended to prevent residual paralysis and complications, emphasizing the importance of close patient monitoring 3
The frequency of residual neuromuscular blockade is estimated to be 28% in children who receive neuromuscular blockers, highlighting the need for careful monitoring and reversal strategies 3

Consider non-pharmacological alternatives, such as physical therapy, heat therapy, and gentle stretching exercises, to reduce the need for muscle relaxants and minimize risks 6
Avoid combining muscle relaxants with other CNS depressants when possible, as this can increase the risk of adverse events, and always prioritize patient safety 6